WORLD-BRANDING-AWARDS
11.3.2021 18:02:08 CET | Business Wire | Press release
The prestigious World Branding Awards, the ultimate global brand recognition accolade – now in its 12th edition, saw over 400 brands from more than 45 countries named “Brand of the Year” in the 2020-2021 World Branding Awards, nominated by over 250,000 consumers across the globe.
Amongst the top tier brands listed as Global Tier winners are CoCo, Fender, Heinz, IKEA, LEGO, Lurpak, McCain, Netflix, PILOT, Spotify, Yakult, and Yamaha, amongst others.
Regional Tier winners include Anchor (New Zealand), Cotton On (Australia), Elkjøp (Norway), LuLu (United Arab Emirates), Isetan and Uniqlo (Japan), and Stimorol (Denmark), amongst others.
National tier winners were no small brands including Arla Buko (Dairy Products – Cream Cheese), Bang & Olufsen (Technology – Audio Products), Mikkeller (Beer), and Pandora (Jewellery), amongst others.
In a truly glamorous achievement, LEGO returned as Global Tier winner in the ‘Toys’ category, and Lurpak made a name as Global Tier winner in the ‘Dairy Products – Butter’ category.
Winners are uniquely judged through three streams: brand valuation, consumer market research, and public online voting. Seventy percent of the scoring process comes from consumer votes. There can only be one winner in each category per country.
The voting and nomination had taken place amidst the global COVID-19 pandemic whilst many countries were faced with restriction measures that had greatly disrupted the economic landscape. The Awards celebrates the innovative and creative ways these successful brands have managed to remain distinct and relevant to their consumers over the past year.
“This is a celebration of the best marketers from across the globe. The Awards are an acknowledgment of the tireless effort of the teams that build and maintain their brand presence in an ever-changing market,” said Richard Rowles, Chairman of the World Branding Forum.
Now in its seventh year, the awards are organised by the World Branding Forum, a global non-profit organisation dedicated to advancing branding standards. It organises and sponsors a range of educational programmes.
For the full list of winners, visit awards.brandingforum.org .
About the World Branding Forum
The World Branding Forum (WBF) is a registered global non-profit organisation. Its aims and activities are to raise the standards in branding for the good of the industry as well as consumers. The WBF produces, manages and supports a wide range of programmes covering research, development, education, recognition, networking and outreach. For more information, visit brandingforum.org .
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005746/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release
DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release
Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom